← back to search

Weining Robieson

AbbVie (United States) · US
Area of research
Neurology · Speech and Hearing
Research interest
Research interests include Medicine, Parkinson's disease, Carbidopa, Levodopa, Dyskinesia, and Physical therapy.
h-index
citations
1,480
works
10
NIH funding
primary concept
email

Recent publications

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Neurology and Therapy 2023cited by 104position: middledoi
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
The Lancet Neurology 2022cited by 190position: middledoi
<scp>DUOGLOBE</scp>: One‐Year Outcomes in a <scp>Real‐World</scp> Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
Movement Disorders Clinical Practice 2021cited by 42position: middledoi
Efficacy and safety of foslevodopa/foscarbidopa versus oral carbidopa/levodopa in advanced Parkinson's disease patients: Design of a phase 3, randomized, double-blind, double-dummy, active controlled 12-week trial
Journal of the Neurological Sciences 2021cited by 2position: middledoi
Application of the ‘5-2-1’ Screening Criteria in Advanced Parkinson’s Disease: Interim Analysis of DUOGLOBE
Neurodegenerative Disease Management 2020cited by 50position: middledoi
Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
Journal of Parkinson s Disease 2019cited by 41position: middledoi
Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease
Movement Disorders 2018cited by 93position: middledoi
Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
European Journal of Neurology 2018cited by 31position: middledoi
Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label results
Movement Disorders 2014cited by 237position: middledoi
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
The Lancet Neurology 2013cited by 690position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David G. Standaert · University of Alabama at Birmingham8 papers (2013–2023)Angelo Antonini · Delft University of Technology5 papers (2013–2023)Lars Bergmann · University Hospital Frankfurt4 papers (2018–2021)Maurizio Facheris · AbbVie (United States)4 papers (2018–2023)Victor S.C. Fung · The University of Sydney4 papers (2014–2023) · 4 papers (2020–2023)К. Ray Chaudhuri · UK Dementia Research Institute4 papers (2018–2023)Alberto J. Espay · University of Cincinnati3 papers (2013–2018)Janet Benesh · AbbVie (United States)3 papers (2013–2018)Hubert H. Fernandez · Universidade Federal do Rio Grande do Sul3 papers (2013–2018)Pavnit Kukreja · AbbVie (United States)3 papers (2019–2021)Krai Chatamra · AbbVie (United States)3 papers (2013–2018)Coleen Hall · AbbVie (United States)2 papers (2014–2018)Saritha Talapala · AbbVie (United States)2 papers (2022–2023)Werner Poewe · Management Center Innsbruck2 papers (2018–2019)Kumar Budur · AbbVie (United States)2 papers (2022–2023) · 2 papers (2020–2021) · 2 papers (2020–2021)Robert Iansek · Monash University2 papers (2020–2021) · 2 papers (2020–2021)